| 1.2 0.02 (1.69%) | 01-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.69 | 1-year : | 1.92 |
| Resists | First : | 1.44 | Second : | 1.64 |
| Pivot price | 1.42  |
|||
| Supports | First : | 1.12 | Second : | 0.93 |
| MAs | MA(5) : | 1.26 |
MA(20) : | 1.43 |
| MA(100) : | 1.49 |
MA(250) : | 1.57  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.5 |
D(3) : | 7.9 |
| RSI | RSI(14): 33.9 |
|||
| 52-week | High : | 3.58 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NNVC ] has closed above bottom band by 6.6%. Bollinger Bands are 78.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.21 - 1.22 | 1.22 - 1.23 |
| Low: | 1.1 - 1.11 | 1.11 - 1.12 |
| Close: | 1.18 - 1.2 | 1.2 - 1.21 |
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Wed, 08 Jan 2025
NanoViricides (NYSE:NNVC) Trading Down 5% – Should You Sell? - Defense World
Tue, 26 Nov 2024
NanoViricides (AMEX:$NNVC) Leads Innovation in Broad-Spectrum Antiviral Therapies - openPR
Sun, 20 Oct 2024
Interview with the President and Executive Chairman: NanoViricides, Inc. (NYSEAMERICAN:NNVC) - The Wall Street Transcript
Mon, 14 Oct 2024
NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy - Yahoo Finance
Wed, 31 Jul 2024
NNVC: NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift in Viral Therapy - Yahoo Finance
Tue, 30 Apr 2024
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon - Charlotte Observer
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 4.5 (%) |
| Held by Institutions | 11.3 (%) |
| Shares Short | 473 (K) |
| Shares Short P.Month | 348 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.89 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.8 % |
| Return on Equity (ttm) | -65.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -1.47 |
| PEG Ratio | 0 |
| Price to Book value | 1.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|